Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Coverage
Overview
Video
Coverage
Coverage
8-Apr-2022
Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans
28-Feb-2022
Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma
24-Feb-2022
Kazia Therapeutics delivers on plans with two promising assets in human trials
12-Dec-2021
Kazia Therapeutics appoints US-based CFO to assist global market expansion
9-Dec-2021
Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter
3-Dec-2021
Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug
3-Dec-2021
ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?
2-Dec-2021
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up
29-Nov-2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
15-Nov-2021
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
Previous
1
2
3
4
5
6
7
Next
